NCT05204017Recruiting
Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
CAPTURE ALS is a long-term data and biorepository platform that will facilitate future ALS research. CAPTURE ALS will provide the standardized systems and tools necessary to collect, store, and analyze vast amounts of multimodal information about ALS. These multimodal datasets and biosamples will be made available for use by researchers or industry across Canada and around the world in accordance with the CAPTURE ALS Data Sharing Policy to advance research on ALS.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 29 Nov 2021
- Start date
- 12 Sept 2021
- Primary completion date
- Dec 2031
- Lead sponsor
- University of Alberta
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT05204017
What you commit to
- Study type: Observational
- Planned participants: 150
- From 12 Sept 2021 to the primary completion date, Dec 2031
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- A history of a neurological disease, including Central Nervous System disease (e.g., stroke, head injury, epilepsy) or Peripheral Nervous System disease (neuropathy, myopathy)
- A history of psychiatric disease (e.g. depression, bipolar disease) that is clinically diagnosed and/or with the current use of psychiatric medications (e.g. antidepressants) for an indication of a psychiatric disease.
Other
- N/A
- \[HEALTHY CONTROLS\]
- Subjects ineligible for an MRI due to a pacemaker or other contraindication according to local MRI policies of the study centre.
- Significant claustrophobia that would prohibit an MRI (subjects will be required to lie in an MRI scanner for approximately one hour).
Who the study is looking for
- Has ALS, classified as definite, probable, laboratory-supported probable, or possible ALS according to the revised El Escorial criteria or a related neurodegenerative disorder including ALS-FTD, PLS, PMA or asymptomatic individuals with a known ALS mutation (as previously confirmed during regular clinical care)
- Be of the age of majority in their province of residence/treatment
- Have the cognitive capacity to provide informed consent
- Have proficiency in English or French in order to understand study instructions and respond to questionnaires
- Be between the ages of 40-80 unless age matched to a patient (+/-3 years) who is already enrolled
- Be the age of majority in their province of residence/treatment
- Have the cognitive capacity to provide informed consent
- Have proficiency in English of French to understand study instructions and respond to questionnaires
Criteria the registry did not label
- \[PATIENTS\]
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alberta Coordinator of this site? Confirm its status | Edmonton | Canada | Recruiting |
| McGill University / Montreal Neurological Institute and Hospital Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
| CHU de Quebec -Universite de Laval Coordinator of this site? Confirm its status | Québec | Canada | Recruiting |
| University of Toronto / Sunnybrook Health Sciences Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.